🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The race to develop more effective #weightloss drugs Nature News & Views #obesity nature.com/articles/d4158… Elie Dolgin

🧵Just released! Our The Lancet Gastroenterology & Hepatology review explores the latest AUD management from a gastro/hepatology perspective 👉authors.elsevier.com/c/1kc078nByrCi…. ⬇️ Juan Pablo (JP) Arab, MD  Ramon Bataller Lorenzo Leggio MASLD Research Center UCSD Gastroenterology Facultad Medicina UC #LiverTwitter ALEH AASLD EASL Education

🌙Ramadan Kareem to all who are celebrating! To all those #gitwitter and #livertwitter friends providing GI and Liver care to fasting patients, please 👀 our recently published guidance in The Lancet Gastroenterology & Hepatology: thelancet.com/journals/langa… 🙏🏼

Clinical guidelines propose that patients with alcohol-related liver disease should be seen within a MULTIDISCIPLINARY CLINIC, but, is there any evidence supporting this ? This recent study in Hepatology Communications by Jessica L. Mellinger shows its beneficial effects.

"The important thing is not to stop questioning. Curiosity has its own reason for existing." – Albert Einstein After five decades, steroid dosing in AAH is revisited: Tapered prednisolone proves superior in reducing infections. #STASH trial now AJG - The American Journal of Gastroenterology journals.lww.com/ajg/abstract/9…

ILTS The ILTS Consensus Conference on Live Donor Safety .. 14th March 2025.. Pooja Bhangui Nazia Selzner

💡Can people with obesity reach a “normal” weight through diet & lifestyle alone? A massive UK study of 177,000+ adults says… not easily. 📉 Over 9 years (no surgery involved): For those with class 1 obesity (BMI 30–34.9): 🔹Men: 1 in 210 reached normal weight 🔹Women: 1 in 124

In Moderate AH: 🦠 Primary causes of death: MOF and infections ‼️Survival rates at 30 were 94.3%, ❌Mortality prediction models showed poor performance. 👴🏼Older, higher freq. women, lower prevalence of cirrhosis and AKI(vs. sAH) Juan Pablo (JP) Arab, MD  Luis Antonio Díaz, MD Ramon Bataller

The Difficult Colonoscopy is humbling to all endoscopists. My Pearls : #1 Female Patients If hysterectomy or diverticulitis, use pedi colonoscope + water immersion. (Angulated colon) If chronic idiopathic constipation or visceral obese, use adult colonoscope (redundant colon)

The aim of this study was to create a deep learning model that analyzed MRI to detect early-stage pCCA and compare its diagnostic performance with expert radiologists. Julie Heimbach Timucin Taner Ty Diwan Nicholas F LaRusso, M.D. Sumera Ilyas #Cholangiocarcinoma bit.ly/3Y4HLNM

How good are we at preventing HIV? How do efficacy and effectiveness differ? In the latest episode of Beyond Journal Club, the hosts journey from oral preexposure prophylaxis (PrEP) to long-acting injectables and then to the PURPOSE trials, which look at the use of long-acting

Very important paper led by Arun J. Sanyal In patients with MASH and F2-3, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The findings in fibrosis are very interesting and encouraging, let’s go now for ALD! #LiverTwitter #LiverX

🆕CPG in press❕ EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma Find it here👉bit.ly/4iTmgqI EASLnews EASL Education

🆕CPG in press❕ EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Find it here👉bit.ly/4deZHf1 EASLnews EASL Education

🆕CPG in press❕ EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease Find it here👉bit.ly/3GM9EEB EASLnews EASL Education

Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) nej.md/44ZeMPz EASO | #ECO2025

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: NEJM 🥸 SURMOUNT-5 Trial: Wow! 😱 Summary 👇👇👇

📢 It’s OVER. The “lean MASLD paradox”? Just bad measurement. ❎MASLD with overweight BMI weren’t healthier! We were using the wrong metric. ↗️Waist circumference-related indices show a dose-dependent mortality risk across 3 prospective cohorts. Let’s reframe how we assess

Thanks to CIHR for supporting our national project to develop novel AI tools for improved equity and outcomes along the liver transplant patient journey! With Co-PIs Jennifer Flemming #DivyaSharma Patricia Gongal, PhD Rahul G. Krishnan with support of Canadian Donation and Transplant Research Program Ajmera Transplant Centre UHN PSC Partners Canada